LONDON (Reuters) - AstraZeneca's sales fell by a bigger-than-expected 13 percent in the first quarter as patent expiries sent revenue from key medicines skidding lower, underscoring the turnaround challenge facing Britain's second biggest drugmaker.
via Reuters: Health News Read More Here..
No comments:
Post a Comment